Clinical Trials

A Study of Enzalutamide and Mifepristone in Treating Patients With Prostate Cancer

Number: NCT02012296
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1| Phase 2
Sponsor(s): University of Chicago|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Number: NCT02452008
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Number: NCT02516670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With and Without Ribociclib for mCRPC patients who have not received chemotherapy

Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors

Number: NCT02744287
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bellicum Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Number: NCT02769962
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With mCRPC

Number: NCT02807805
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Chong-xian Pan|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Number: NCT02903160
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Icahn School of Medicine at Mount Sinai|Sanofi|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1| Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): University of California, Davis|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Number: NCT02975934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Clovis Oncology, Inc.|Foundation Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Number: NCT02985021
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seattle Institute for Biomedical and Clinical Research|Prostate Cancer Foundation|VA Puget Sound Health Care System
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

Number: NCT02985957
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With mCRPC With DNA Repair Defects

Number: NCT03012321
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|AstraZeneca|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Clinical Study of change in brain structure or activity in men treated with androgen receptor therapies such as abiraterone acetate and enzalutamide

Number: NCT03016741
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Northwestern University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With mCRPC

Number: NCT03098836
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Daniel George, MD|Janssen Scientific Affairs, LLC|Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Number: NCT03170960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Using Imaging for Detection of mCRPC

Number: NCT03173924
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Number: NCT03207867
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Number: NCT03217747
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Number: NCT03246347
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Earle Burgess, MD|Astellas Pharma Inc|Medivation, Inc.|Atrium Health
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pembrolizumab in mCRPC With or Without DNA Damage Repair Defects

Number: NCT03248570
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Number: NCT03298087
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Number: NCT03304418
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone

Number: NCT03317392
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Number: NCT03344211
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC With Deoxyribonucleic Acid (DNA) Damage Repair Deficiencies (DDR)

Number: NCT03395197
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With mCRPC

Number: NCT03414034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Trovagene, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Niraparib Combination Therapies for the Treatment of mCRPC

Number: NCT03431350
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Number: NCT03437941
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Corcept Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Number: NCT03442556
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Number: NCT03456843
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

Number: NCT03490838
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Advanced Accelerator Applications
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)

Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer

Number: NCT03516812
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Number: NCT03531827
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

Number: NCT03565835
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Montefiore Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of HPN424 in Patients With Advanced Prostate Cancer

Number: NCT03577028
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Number: NCT03585114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Emerson Lim|Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s)
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
MGC018 With or Without MGA012 in Advanced Solid Tumors

Number: NCT03729596
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03751436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Roswell Park Cancer Institute|National Cancer Institute (NCI)|AbbVie
Sponsor Trial Information
Trial Location(s) and Contact(s)
To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Number: NCT03752099
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Veru Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects with MCRPC

Number: NCT03792841
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Number: NCT03800784
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2| Phase 3
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer

Number: NCT03824275
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2| Phase 3
Sponsor(s): Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Number: NCT03834493
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Number: NCT03834506
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Number: NCT03834519
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Number: NCT03837353
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NYU Langone Health|Leap Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Number: NCT03850795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Hinova Pharmaceuticals USA, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Number: NCT03866382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03888612
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arvinas Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

Number: NCT03899467
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer

Number: NCT03934840
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Masonic Cancer Center, University of Minnesota
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone

Number: NCT03939689
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

Number: NCT03972657
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Number: NCT03999515
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)|Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Number: NCT04028388
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Modra Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Number: NCT04032704
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seattle Genetics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04033432
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|Vasgene Therapeutics, Inc|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Number: NCT04060342
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.|MSD International GmbH (Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.)|Gossamer Bio Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Number: NCT04060394
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Laekna Limited
Sponsor Trial Information
Trial Location(s) and Contact(s)
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Number: NCT04090528
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|Merck Sharp & Dohme Corp.|Madison Vaccines, Inc|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Number: NCT04090775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rampart Health, L.L.C.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Number: NCT04100018
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Checkpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Number: NCT04104893
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Number: NCT04116775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Julie Graff, MD|Merck Sharp & Dohme Corp.|Prostate Cancer Foundation|Johns Hopkins University|Oregon Health and Science University|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

Number: NCT04157088
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Number: NCT04158245
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tulane University|Blue Earth Diagnostics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Number: NCT04207255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04221542
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): http://www.amgentrials.com/amgen/studysearch.aspx?SearchStr=amg+160
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

Number: NCT04237584
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): MANA RBM|Bayer|Carolina Urologic Research Center|Tulane University|Barbara Ann Karmanos Cancer Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients

Number: NCT04246671
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bavarian Nordic
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Number: NCT04253262
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Brown University|Rhode Island Hospital|The Miriam Hospital|Bayer|Clovis Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Number: NCT04381832
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Number: NCT04382898
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): BioNTech SE
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Number: NCT04446117
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Exelixis|Roche-Genentech|Takeda
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy

Number: NCT04471727
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Number: NCT04471974
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Zenith Epigenetics|Merck Sharp & Dohme Corp.|U.S. Army Medical Research and Development Command|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Number: NCT04495179
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca|Parexel
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic

Number: NCT04497844
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Number: NCT04503265
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): AtlasMedx, Incorporated
Sponsor Trial Information
Trial Location(s) and Contact(s)
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Number: NCT04556617
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): PlexxikonPlexxikon
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Number: NCT04564027
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s)

Total: 87 Clinical Trials























PHEN,Inc. © 2021 All rights reserved